Osteoporosis, a condition that weakens bones and heightens the risk of fractures, poses a significant public health challenge, especially among postmenopausal women. The disease stems from an imbalance between bone formation by osteoblasts and bone resorption by osteoclasts. While current treatments primarily aim to slow bone loss, they fall short in effectively promoting bone formation. Moreover, the molecular mechanisms governing the differentiation of bone marrow mesenchymal stem cells (BMSCs) into osteoblasts or adipocytes remain poorly understood. These gaps underscore the urgent need for novel molecular targets that can enhance bone formation while curbing bone resorption.
A transformative study has uncovered the pivotal role of the protein Naked cuticle homolog 2 (NKD2) in regulating the differentiation of bone-forming osteoblasts and bone-resorbing osteoclasts. This discovery opens up new possibilities in the fight against bone loss, particularly in postmenopausal osteoporosis. The research suggests that NKD2 not only promotes osteoblast differentiation but also inhibits adipocyte formation and osteoclast activity, positioning it as a potential therapeutic target for metabolic bone disorders. The study also sheds light on the intricate interplay between Wnt/β-catenin and mTORC1 signaling pathways, key regulators of bone homeostasis.
Naked cuticle (NKD), encoded by the Drosophila segment polarity gene, is an EF hand protein that acts as an antagonist of the Wnt pathway by directly interacting with the Wnt signalosome component Dishevelled (Dvl). In vertebrates, there are two NKD homologs, NKD1 and NKD2, both of which can antagonize canonical and non-canonical Wnt signaling pathways. NKD2 can suppress tumor growth and/or metastasis in osteosarcoma, esophageal cancer and liver cancer at least partly affecting the Wnt/β-catenin signaling. It has recently been reported that NKD2 stimulates the differentiation of dental follicle stem/progenitor cells, though it is unknown whether NKD2 in BMSCs has a role in the differentiation of osteoblasts, adipocytes, and osteoclasts.
The recent study led by researchers from Tianjin Medical University in China has identified NKD2 as a critical regulator of bone cell differentiation that also inhibits adipocyte formation and suppresses osteoclast activity. Through its regulation of Wnt/β-catenin and mTORC1 signaling pathways, NKD2 plays a crucial role in maintaining bone homeostasis, offering a promising new approach for treating osteoporosis and other bone-related disorders. The study demonstrates that NKD2 is upregulated during the differentiation of bone marrow mesenchymal stem cells (BMSCs) into osteoblasts and adipocytes. Functional experiments show that overexpressing NKD2 enhances osteoblast differentiation while suppressing adipocyte formation.
Mechanistically, NKD2 activates Wnt/β-catenin signaling in differentiating cells but suppresses it in undifferentiated cells, underscoring its context-dependent role. The protein also interacts with tuberous sclerosis complex subunit 1 (TSC1), a key regulator of the mTORC1 pathway, further influencing bone cell differentiation. In vivo experiments on ovariectomized mice, a model for postmenopausal osteoporosis, demonstrated that transplanting NKD2-overexpressing BMSCs significantly improved bone mass by increasing osteoblast numbers and reducing adipocyte formation. Additionally, NKD2 downregulates RANKL, a crucial factor for osteoclast differentiation, leading to reduced bone resorption.
These findings position NKD2 as a dual-action therapeutic target-promoting bone formation while inhibiting bone loss and its discovery as a critical regulator in bone homeostasis holds immense promise for therapeutic interventions in osteoporosis and other bone disorders like tuberous sclerosis, osteogenesis imperfecta or Crouzon syndrome. Targeting NKD2 could pave the way for treatments that not only prevent bone loss but also promote bone formation, addressing a long-standing gap in osteoporosis management. Moreover, the study’s findings could lead to the development of novel biomarkers for early diagnosis and personalized treatment strategies. Future research will focus on translating these discoveries into clinical applications, potentially revolutionizing how we treat bone diseases.
- edited by Dr. Gianfrancesco Cormaci, PhD, specialist in Clinical Biochemistry.
Scientific references
Shan L, Liao X et al. Genes Dis. 2024;12(1):101209.
Yang X, Chen M et al. Stem Cells. 2024; 42(7):662-674.
Morsczeck C. Int J Mol Sci. 2022 May 25; 23(11):5945.
Chen C et al. Int J Mol Med. 2018; 42(5):2403-2414.
